Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ketoprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 6/20 | 0.97 |
| ▸ | PTGS2 known ✓ | P35354 | 6/20 | 0.97 |
| ▸ | MAPT | P10636 | 5/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.97 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | RECQL | P46063 | 1/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | HPGD | P15428 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.97 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.97 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.97 |
| ▸ | THPO | P40225 | 1/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.97 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexketoprofen SCHEMBL6357571 | 1.00 | PTGS1 (0.97) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| R-Ketoprofen SCHEMBL29353694 | 0.98 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| Ketoprofen SCHEMBL3843886 | 0.98 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| Dexketoprofen SCHEMBL66987 | 0.98 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| Ketoprofen SCHEMBL16757741 | 0.98 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| Dexketoprofen SCHEMBL29396875 | 0.98 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| Ketoprofen SCHEMBL679920 | 0.98 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| R-Ketoprofen SCHEMBL195303 | 0.98 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| Ketoprofen SCHEMBL8754790 | 0.98 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| Ketoprofen SCHEMBL8577572 | 0.98 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250375395-A1 | TRANSDERMAL FORMULATION AND DELIVERY METHOD OF LOW SOLUBILITY OR UNSTABLE UNIONIZED NEUTRAL DRUGS BY IN SITU SALT-TO-NEUTRAL DRUG CONVERSION OF SALT DRUG | CORIUM INTERNATIONAL, INC. | 2025-12-11 | — | — | US | claimed |
| CN-116270551-A | Composition for in-situ conversion from salt to neutral drug, transdermal patch and application | 考里安有限责任公司 | 2023-06-23 | — | — | CN | claimed |
| EP-3490541-A2 | TRANSDERMAL FORMULATION AND DELIVERY METHOD OF LOW SOLUBILITY OR UNSTABLE UNIONIZED NEUTRAL DRUGS BYIN SITU | Corium International, Inc. (US) | 2019-06-05 | — | — | EP | claimed |
| CN-109789105-A | Transdermal formulations and methods of delivery of low solubility or unstable non-ionized neutral drugs by in situ conversion of salts of the salt drug to the neutral drug | 考里安国际公司 | 2019-05-21 | — | — | CN | claimed |
| WO-2018022815-A2 | TRANSDERMAL FORMULATION AND DELIVERY METHOD OF LOW SOLUBILITY OR UNSTABLE UNIONIZED NEUTRAL DRUGS BY IN SITU SALT-TO-NEUTRAL DRUG CONVERSION OF SALT DRUG | CORIUM INTERNATIONAL, INC. (US) | 2018-02-01 | — | — | WO | claimed |
| US-20180028463-A1 | TRANSDERMAL FORMULATION AND DELIVERY METHOD OF LOW SOLUBILITY OR UNSTABLE UNIONIZED NEUTRAL DRUGS BY IN SITU SALT-TO-NEUTRAL DRUG CONVERSION OF SALT DRUG | COLUMBUS INVESTMENT HOLDINGS SA (CH) | 2018-02-01 | — | — | US | claimed |
| EP-2709598-A1 | PHARMACEUTICAL COMPOSITION COMPRISING KETOPROFEN | Aventis Pharma S.A. (FR) | 2014-03-26 | — | — | EP | claimed |
| US-20140073698-A1 | PHARMACEUTICAL COMPOSITION COMPRISING KETOPROFEN | AVENTIS PHARMA S.A. (FR) | 2014-03-13 | — | — | US | claimed |
| WO-2012159962-A1 | PHARMACEUTICAL COMPOSITION COMPRISING KETOPROFEN | AVENTIS PHARMA S.A. (FR) | 2012-11-29 | — | — | WO | claimed |
| US-20100197791-A1 | PHARMACEUTICALS FOR TRANSDERMAL USE ON ANIMALS | BAYER ANIMAL HEALTH GMBH (DE) | 2010-08-05 | — | — | US | claimed |
| US-20100015049-A1 | METHODS AND COMPOSITIONS FOR TREATING POSTOPERATIVE PAIN COMPRISING NONSTEROIDAL ANTI-INFLAMMATORY AGENTS | WARSAW ORTHOPEDIC, INC. (US) | 2010-01-21 | — | — | US | claimed |
| WO-2010009116-A2 | METHODS AND COMPOSITIONS FOR TREATING POSTOPERATIVE PAIN COMPRISING NONSTEROIDAL ANTI-INFLAMMATORY AGENTS | WARSAW ORTHOPEDIC, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| US-20080038316-A1 | Conveniently implantable sustained release drug compositions | RAMSCOR, INC. | 2008-02-14 | — | — | US | claimed |
| WO-1996016017-A1 | NOVEL ARYLPROPIONIC DERIVATIVES WITH ANALGESIC ACTION AND THE PROCESS FOR THE PREPARATION THEREOF | LABORATORIOS MENARINI S.A. (ES) | 1996-05-30 | — | — | WO | claimed |
| US-20260144751-A1 | LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF | PHARMOSA BIOPHARM INC. (TW) | 2026-05-28 | — | — | US | disclosed |
| US-12551437-B2 | Liposome compositions comprising weak acid drugs and uses thereof | PHARMOSA BIOPHARM INC. (TW) | 2026-02-17 | — | — | US | disclosed |
| US-12528760-B2 | Co-crystal of ketoprofen and its preparation, pharmaceutical compositions comprising the same and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2026-01-20 | — | — | US | disclosed |
| WO-1994011332-A1 | A NOVEL ARYLPROPIONIC DERIVATIVE, A PROCESS FOR THE PREPARATION AND THE USE THEREOF AS AN ANALGESIC AGENT | LABORATORIOS MENARINI S.A. (ES) | 1994-05-26 | — | — | WO | disclosed |
| US-5254338-A | N-vinylacetamide polymer | SHOWA DENKO K.K. (JP) | 1993-10-19 | — | — | US | disclosed |
| EP-0446636-A2 | External application base or auxiliary agent and external application composition for human being or animal containing the same | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1991-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144751-A1 | LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF | LIPA, NSF, SLC26A3 | PTGS1 2168/4885PTGS2 1549/4885MAPT 3202/4885 |
| US-20100015049-A1 | METHODS AND COMPOSITIONS FOR TREATING POSTOPERATIVE PAIN COMPRISING NONSTEROIDAL ANTI-INFLAMMATORY AGENTS | PTGES3, PTGS1, PTGES | PTGS1 2/4885PTGS2 8/4885MAPT 3499/4885 |
| US-12551437-B2 | Liposome compositions comprising weak acid drugs and uses thereof | SLC26A3, LIPA, NSF | PTGS1 1556/4885PTGS2 1387/4885MAPT 3345/4885 |
| US-12528760-B2 | Co-crystal of ketoprofen and its preparation, pharmaceutical compositions comprising the same and uses thereof | KMO, KCNK5, KLK5 | PTGS1 204/4885PTGS2 362/4885MAPT 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.